Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

por McNeel, Douglas G, Eickhoff, Jens C, Wargowski, Ellen, Johnson, Laura E, Kyriakopoulos, Christos E, Emamekhoo, Hamid, Lang, Joshua M, Brennan, Mary Jane, Liu, Glenn
Publicado 2022